Critical Contrast: Pliant Therapeutics (NASDAQ:PLRX) and Pluri (NASDAQ:PLUR)

Pluri (NASDAQ:PLUR) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, profitability, analyst recommendations, institutional ownership, valuation and dividends.

Analyst Ratings

This is a summary of recent ratings and price targets for Pluri and Pliant Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pluri	1	0	0	0	1.00
Pliant Therapeutics	2	1	1	0	1.75

Pliant Therapeutics has a consensus target price of $3.00, suggesting a potential upside of 162.01%. Given Pliant Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Pliant Therapeutics is more favorable than Pluri.

Earnings & Valuation

This table compares Pluri and Pliant Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pluri	$1.34 million	13.85	-$22.58 million	($4.53)	-0.38
Pliant Therapeutics	N/A	N/A	-$149.34 million	($1.49)	-0.77

Pluri has higher revenue and earnings than Pliant Therapeutics. Pliant Therapeutics is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Pluri and Pliant Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pluri	-2,162.08%	N/A	-106.59%
Pliant Therapeutics	N/A	-52.17%	-40.46%

Institutional and Insider Ownership

16.6% of Pluri shares are owned by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are owned by institutional investors. 43.2% of Pluri shares are owned by company insiders. Comparatively, 8.7% of Pliant Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

Pluri has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, Pliant Therapeutics has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500.

Summary

Pliant Therapeutics beats Pluri on 8 of the 13 factors compared between the two stocks.

About Pluri

Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

About Pliant Therapeutics

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.